Actos Bladder Cancer eJustice Commercial - The U.S. Food and Drug Administration (FDA) said in 2011 that persons who take Actos for more than one year have a greater risk for developing bladder cancer. That same year, sales of Actos were put on hold in Germany and France over concerns of the potential health risks. But, despite the risks, Actos remains on the market in the U.S. Visit http://www.ejustice.org for more information.
